CTOs on the Move

C2i Genomics

www.c2i-genomics.com

 
C2i Genomics is the first company to offer post-surgery monitoring of cancer recurrence and progression by analyzing subtle changes in the pattern of the tumor`s DNA. Our liquid biopsy Whole Genome assay and cancer burden score will equip oncologists with vital timely information months to years before current monitoring methods are able to.
  • Number of Employees: 0-25
  • Annual Revenue: $0-1 Million

Executives

Name Title Contact Details

Funding

C2i Genomics raised $12M on 06/09/2020
C2i Genomics raised $100M on 04/15/2021

Similar Companies

BioTek Instruments

BioTek Instruments is a worldwide leader in the development of high performance, bioanalytical measurement systems and software. Our representatives worldwide call on a variety of customers including academic, government, and biotech/pharmaceutical. We

Biocentric Solutions

Biocentric Solutions, Inc. is a Madison, WI-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Partner Therapeutics

Partner Therapeutics is devoted to developing and commercializing cancer medicines and combination therapies that can make a meaningful difference in the lives of cancer patients.

Sigma-Tau Pharmaceuticals

Sigma-Tau Pharmaceuticals is a Gaithersburg, MD-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Plexium

Plexium is the premier, next-generation Targeted Protein Degradation (TPD) company seeking to discover a wide range of monovalent target protein degraders that address the limitations of heterobifunctional degraders and cereblon IMiDs. The company is powered by its proprietary drug discovery platform designed to identify novel small molecules that induce selective degradation of drug target proteins through E3 ligase mediated proteasomal degradation. From molecular glues to monovalent degraders, Plexium is advancing a pipeline of novel targeted protein degraders for the treatment of cancer, neurodegeneration, and other diseases. Due to its expertise in TPD, Plexium has entered into strategic collaborations with Amgen and AbbVie to discover and develop a wide range of new therapies from cancer to neurological diseases. Supported by high quality investors, Plexium is well positioned to transform medicine.